{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:44:30Z","timestamp":1792615470512,"version":"4.5.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Feline Medicine and Surgery"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The study aimed to evaluate the efficacy and safety of insulin glargine 300\u2009U\/ml (IGla-U300) in cats with variable duration of diabetes mellitus (DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirteen client-owned cats with DM completed a prospective clinical trial. Four cats were highly suspected of hypersomatotropism and excluded from the insulin efficacy evaluation. All cats were treated with IGla-U300 SC at a starting dosage of 0.5\u2009U\/kg q12h and fed with a low carbohydrate diet. Cats were monitored for 8 weeks with a once-weekly at-home 16\u2009h blood glucose curve (BGC) and a questionnaire evaluating the presence of DM-related clinical signs. In-clinic evaluations, including serum fructosamine measurement, were scheduled within 3 days of the first, third, sixth and eighth BGC. Glycemic variability was assessed by calculating the SD of each BGC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Excluding four cats suspected of hypersomatotropism, at the time of the eighth BGC, improved or absent polyuria, polydipsia, polyphagia, weight loss, lethargy and improved or normal general demeanor were reported in 8\/9 (88%), 8\/9 (88%), 7\/9 (77%), 7\/9 (77%), 7\/9 (77%) and 8\/9 (88%) cats, respectively. Two cats achieved remission after 29 and 53 days. Another two cats went into remission after the end of the study (days 82 and 96). All cats that achieved remission were newly diagnosed diabetics. Median (range) serum fructosamine concentration significantly decreased when comparing the time of enrollment (604 [457\u2013683] \u00b5mol\/l) with the eighth week of treatment (366 [220\u2013738]\u2009\u00b5mol\/l) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02). In all 13 cats, biochemical hypoglycemia (blood glucose &lt;60\u2009mg\/dl; &lt;3.3\u2009mmol\/l) was detected in 13\/104 (12.5%) BGCs, while clinical signs suggesting hypoglycemic episodes were not reported. Glycemic variability was significantly lower at the fifth BGC when comparing cats that achieved remission with cats that did not achieve remission (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.02).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and relevance<\/jats:title>\n                    <jats:p>IGla-U300 seems effective and safe for the treatment of feline diabetes, but more long- term and comparative clinical trials are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1098612x211013018","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T09:43:09Z","timestamp":1621417389000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Insulin glargine 300 U\/ml for the treatment of feline diabetes mellitus"],"prefix":"10.1177","volume":"24","author":[{"given":"Guido","family":"Linari","sequence":"first","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Fleeman","sequence":"additional","affiliation":[{"name":"Animal Diabetes Australia, Mulgrave, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Gilor","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Giacomelli","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-2199","authenticated-orcid":false,"given":"Federico","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-6822"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X15571880"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.05.016"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.04.010"},{"key":"e_1_3_2_6_2","unstructured":"Drugs@FDA. FDA-approved drugs. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=206538 (February 25 2015 accessed September 20 2020)."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0991"},{"key":"e_1_3_2_8_2","article-title":"Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100.","author":"Tillner J","year":"2013","unstructured":"Tillner J, Bergmann K, Teichert L, et al. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100. Diabetes 2013; 62 Suppl 1: A217\u2013A364.","journal-title":"Diabetes"},{"key":"e_1_3_2_9_2","article-title":"New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM).","author":"Dahmen R","year":"2013","unstructured":"Dahmen R, Bergmann K, Lehman A, et al. New insulin glargine U300 formulation evens and prolongs steady state PK and PD profiles during euglycemic clamp in patients with type 1 diabetes (T1DM). Diabetes 2013; 62 Suppl 1: A1\u2013A98.","journal-title":"Diabetes"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0990"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12438"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0249"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12472"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12532"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12485"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12619"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12618"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2020.106595"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2019.04.001"},{"key":"e_1_3_2_20_2","unstructured":"European Society of Veterinary Endocrinology. Project ALIVE. https:\/\/www.esve.org\/alive\/intro.aspx (2017 accessed September 20 2020)."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1024\/0036-7281.151.9.448"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X11432236"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2007.10.013"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0342.x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.12449"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X12446211"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2009.05.016"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2014.08.014"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2010.0598.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.9.1353"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2105"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cvsm.2012.12.001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2007.04.007"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.02.008"},{"key":"e_1_3_2_35_2","first-page":"1659","article-title":"Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data.","volume":"79","author":"Cox DJ","year":"1994","unstructured":"Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 1994; 79: 1659\u20131662.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-007-0820-z"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.13.1445"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0049"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2012.0099"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4423-z"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15134"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.15915"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1396"},{"key":"e_1_3_2_44_2","first-page":"339","article-title":"Glycemic variability in diabetic cats with and without concurrent diseases.","volume":"34","author":"Kr\u00e4mer AL","year":"2020","unstructured":"Kr\u00e4mer AL, Lutz TA, Zini E, et al. Glycemic variability in diabetic cats with and without concurrent diseases. J Vet Intern Med 2020; 34: 339\u2013530.","journal-title":"J Vet Intern Med"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127794"},{"key":"e_1_3_2_46_2","first-page":"1015","article-title":"Comparison of continuous glucose monitoring profiles and glycemic variability during day and night in healthy and diabetic cats.","volume":"33","author":"Schuppisser C","year":"2019","unstructured":"Schuppisser C, Lutz TA, Zini E, et al. Comparison of continuous glucose monitoring profiles and glycemic variability during day and night in healthy and diabetic cats. J Vet Intern Med 2019; 33: 1015\u20131101.","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Feline Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211013018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1098612X211013018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1098612X211013018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:19:40Z","timestamp":1792588780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1098612X211013018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1177\/1098612X211013018"],"URL":"https:\/\/doi.org\/10.1177\/1098612x211013018","relation":{},"ISSN":["1098-612X","1532-2750"],"issn-type":[{"value":"1098-612X","type":"print"},{"value":"1532-2750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}